INFU
InfuSystem Holdings, Inc.
NYSE American Healthcare United States
14,23 $US
+3.57% today
+69.61% YTD · +47.00% 1Y
3
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
24
Hedge funds tracked
Latest available SEC 13F filings
84
/ 100
VERY STRONG

Analysis InfuSystem Holdings, Inc. (INFU) — Kairos Score 84/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Key info

👔
CEO
Ms. Carrie A. Lachance B.S.N., M.B.A., R.N.
📍
HQ
3851 West Hamlin Road, Rochester Hills, MI, 48309, United States
👥
Employees
461
💰
Market cap
283 421 472,00 $US
📊
P/E
35.6
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

3 transactions — 0 buys and 0 sales reported by InfuSystem Holdings, Inc. executives.

FJ
Funke Jerod
EVP-Chief HR Officer · 2026-10-09
Other
FJ
Funke Jerod
EVP-Chief HR Officer · 2026-10-09
Other
SS
Shuda Scott
2026-09-10
Other

🏦 Hedge Funds

24 institutional funds report a position on INFU in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD GROUP INC
VANGUARD CAPITAL MANAGEMENT LLC
AMERICAN CENTURY COMPANIES INC
DIMENSIONAL FUND ADVISORS LP

📰 Recent news

14 recent articles on INFU.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as InfuSystem Holdings, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of INFU on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 3 insider transactions over 90 days
✅ All 24 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year